Modopar 250 (Benserazide Hydrochloride, Levodopa)

Levodopa, the active ingredient in Modopar 250, is a dopaminergic agent presented as a tablet for oral use. It is employed to manage Parkinson's disease and Parkinsonian syndrome in adult patients, improving motor function by replenishing central dopamine levels.

GNH USA supplies Modopar 250 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from comprehensive regulatory support and timely delivery across multiple regions.

Modopar 250, a levodopa/benserazide combination, acts on the dopaminergic pathway to alleviate motor symptoms in Parkinsonian disorders.

- Parkinson's disease: improves bradykinesia, rigidity and tremor, enhancing daily functioning. - Parkinsonian syndrome: reduces motor impairment associated with secondary parkinsonism. - Motor fluctuations in advanced Parkinson's: stabilizes response to dopaminergic therapy and decreases “off” periods.

Modopar 250 may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea - Dizziness or light‑headedness - Orthostatic hypotension - Headache

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Psychosis or hallucinations - Severe hypotension or cardiovascular collapse - Anaphylactic or severe allergic reactions - Neuroleptic malignant syndrome

When prescribing Modopar 250, clinicians should observe several precautionary measures.

- Monitor blood pressure: watch for orthostatic drops especially after dose initiation. - Assess psychiatric status: observe for hallucinations or confusion. - Adjust dose in renal impairment: reduce dosage in patients with decreased renal function. - Avoid abrupt discontinuation: taper to prevent withdrawal symptoms. - Use with caution in elderly: increased sensitivity to side effects. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Modopar 250 can interact with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis. - Antipsychotics that block dopamine receptors (e.g., haloperidol): may diminish therapeutic effect. - High‑dose pyridoxine (vitamin B6): accelerates peripheral levodopa metabolism.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood pressure lowering. - Selective serotonin reuptake inhibitors (SSRIs): potential for serotonin syndrome. - Iron or calcium supplements: may reduce levodopa absorption if taken simultaneously. - Anticholinergic drugs: may increase central side effects.